Document is current
Any future updates will be listed below
-
Authors
Stringhini, Marco
Spadafora, Ilaria
Catalano, Marco
Mock, Jacqueline
Probst, Philipp
Spörri, Roman
Neri, Dario https://orcid.org/0000-0001-5234-7370
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_182003/1)
H2020 European Research Council (670603)
ETH Zurich
- License Information
-
More Information
Article History
Received: 3 December 2020
Accepted: 8 March 2021
First Online: 1 April 2021
Declarations
:
: D.N. is co-founder and shareholder of Philogen SpA (Siena, Italy), a biotech company that owns the F8 and L19 antibodies. The authors have no additional financial interests.
: All the in vivo experiments were conducted under the project license 04/2018, granted by the Veterinäramt des Kantons Zürich (Zurich, Switzerland).
